

FORM PTO-1390 (REV 10-2000)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER 1702.401800
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371			U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) Unassigned 09/743281
INTERNATIONAL APPLICATION NO. PCT/NO99/00220	INTERNATIONAL FILING DATE June 30, 1999	PRIORITY DATE CLAIMED July 8, 1998	
TITLE OF INVENTION ANTIGENIC PEPTIDES DERIVED FROM TELOMERASE			
APPLICANT(S) FOR DO/EO/US Gustav GAUDERNACK, Jon Amund ERIKSEN, Mona MØLLER, Marianne Klemp GJERTSEN, Ingvil SÆTERDAL, and Stein SÆBØE-LARSEN			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
<ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input checked="" type="checkbox"/> This is an express request to promptly begin national examination procedures (35 U.S.C. 371(f)). 4. <input checked="" type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (PCT Article 31). 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> a. <input checked="" type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input checked="" type="checkbox"/> has been communicated by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). 7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> a. <input checked="" type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 			
Items 11. to 16. below concern other document(s) or information included:			
<ol style="list-style-type: none"> 11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. <input checked="" type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 14. <input type="checkbox"/> A substitute specification. 15. <input type="checkbox"/> A change of power of attorney and/or address letter. 16. <input checked="" type="checkbox"/> Other items or information: <ol style="list-style-type: none"> (i) Sequence Listing - Paper Copy (ii) Sequence Listing - Computer Readable Copy (i.e., diskette) (iii) Statement Under 37 CFR §1.821(f) (iv) International Search Report (v) International Preliminary Examination Report 			

U.S. APPLICATION NO. (If known, see 37 CFR 1.49) Unassigned 09/743281		INTERNATIONAL APPLICATION NO. PCT/NO99/00220		ATTORNEY'S DOCKET NUMBER 534 Rec'd PCT/PTO 08 JAN 2001	
---	--	---	--	--	--

17. <input checked="" type="checkbox"/> The following fees are submitted: Basic National Fee (37 CFR 1.492(a)(1)) Neither international preliminary examination (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1000.00 International preliminary examination fee (37 CFR 1.482 not paid to USPTO but International Search Report prepared by the EPO or JPO \$860.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$710.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$690.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00 <div style="text-align: right;">ENTER APPROPRIATE BASIC FEE AMOUNT =</div>				CALCULATIONS		PTO USE ONLY	

Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$			
--	--	--	--	----	--	--	--

Claims	Number Filed	Number Extra	Rate		
Total Claims	33 -20 =	13	X \$18.00	\$	234.00
Independent Claims	2- 3 =	0	X \$80.00	\$	0.00
Multiple dependent claim(s) (if applicable)				+ \$270.00	\$ 270.00
TOTAL OF ABOVE CALCULATIONS =				\$ 1504.00	

<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$			
SUBTOTAL =				\$ 1504.00			

Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$			
TOTAL NATIONAL FEE =				\$ 1504.00			

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$			
TOTAL FEES ENCLOSED =				\$ 1504.00			

				Amount to be:	
				refunded	\$
				charged	\$

a. <input checked="" type="checkbox"/> A check in the amount of \$1504.00 to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>06-1205</u> . A duplicate copy of this sheet is enclosed.	
---	--

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

FITZPATRICK, CELLA, HARPER & SCINTO
 30 Rockefeller Plaza
 New York, NY 10112-3801
 Facsimile: (212) 218-2200

John W. Behringer

 SIGNATURE

 John W. Behringer
 NAME

 23,086
 REGISTRATION NUMBER

 January 8, 2001
 DATE

RECEIVED

20 FEB 2002

09743281.020501

716

1702.401800

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
GUSTAV GAUDERNACK, ET AL.)	: Examiner: Unassigned
)	: Group Art Unit: Unassigned
Int'l Appln. No.: PCT/NO99/00220)	
)	:
Int'l Publn. No.: WO 00/02581)	
)	:
U.S. Appln. No.: 09/743,281)	
)	:
Nat'l Entry Date: January 8, 2001)	
)	:
For: ANTIGENIC PEPTIDES DERIVED)	: February 20, 2002
FROM TELOMERASE)	:

BOX PCT

Commissioner For Patents
Washington, D.C. 20231

STATEMENT UNDER 37 C.F.R § 1.821(f)

Sir:

Applicants hereby submit that the Sequence Listing information recorded in computer readable form on the enclosed diskette is identical to the paper copy of the Sequence Listing filed concurrently herewith.

Applicant's undersigned attorney may be reached in our Washington, D.C. office by telephone at (202) 530-1010. All correspondence should continue to be directed to our address given below.


Respectfully submitted,



John W. Behringer
Registration No. 23,086
Attorney for Applicant

FITZPATRICK, CELLA, HARPER & SCINTO
30 Rockefeller Plaza
New York, New York 10112-3801
Facsimile: (212) 218-2200

DC_MAIN 87524 v 1



20 FEB 2002

13281.07050.1

#6

SEQUENCE LISTING

<110> Gaudernack, Gustav
Eriksen, Jon Amund
Moller, Mona
Gjertsen, Marianne Klemp
Saeterdal, Ingvil
Saeboe-Larsen, Stein

<120> Antigenic Peptides Derived from Telomerase

<130> 1702.401800

<140> US 09/743,281

<141> 2001-07-05

<150> PCT/NO99/00220

<151> 1999-06-30

<160> 19

<170> PatentIn version 3.1

<210> 1

<211> 22

<212> PRT

<213> Homo sapiens

<400> 1

Phe Leu His Trp Leu Met Ser Val Tyr Val Val Glu Leu Leu Arg Ser
1 5 10 15

Phe Phe Tyr Val Thr Glu
20

<210> 2

<211> 16

<212> PRT

<213> Homo sapiens

<400> 2

Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg Phe Ile Pro Lys
1 5 10 15

<210> 3

<211> 16

<212> PRT

<213> Homo sapiens

<400> 3

Asp Gly Leu Arg Pro Ile Val Asn Met Asp Tyr Val Val Gly Ala Arg
1 5 10 15

<210> 4

<211> 18

<212> PRT

<213> Homo sapiens

<400> 4

Gly Val Pro Glu Tyr Gly Cys Val Val Asn Leu Arg Lys Thr Val Val
1 5 10 15

Asn Phe

```
<210> 5
<211> 23
<212> PRT
<213> Homo sapiens
```

<400> 5

Lys Phe Leu His Trp Leu Met Ser Val Tyr Val Val Glu Leu Leu Arg
1 5 10 15

Ser Phe Phe Tyr Val Thr Glu
20

```
<210> 6
<211> 17
<212> PRT
<213> Homo sapiens
```

<400> 6

Lys Phe Leu His Trp Leu Met Ser Val Tyr Val Val Glu Leu Leu Arg
1 5 10 15

Ser

```
<210> 7
<211> 18
<212> PRT
<213> Homo sapiens
```

<400> 7

Leu Met Ser Val Tyr Val Val Glu Leu Leu Arg Ser Phe Phe Tyr Val
1 5 10 15

Thr Glu

<210> 8

<400> 8
000

```
<210> 9
<211> 9
<212> PRT
<213> Homo sapiens
```

<400> 9

Ile Leu Ala Lys Phe Leu His Trp Leu
1 5

<210> 10

<211> 9

<212> PRT

<213> Homo sapiens

<400> 10

Glu Leu Leu Arg Ser Phe Phe Tyr Val
1 5

<210> 11

<211> 9

<212> PRT

<213> Homo sapiens

<400> 11

Leu Met Ser Val Tyr Val Val Glu Leu
1 5

<210> 12

<211> 9

<212> PRT

<213> Homo sapiens

<400> 12

Thr Ser Arg Leu Arg Phe Ile Pro Lys
1 5

<210> 13

<211> 9

<212> PRT

<213> Homo sapiens

<400> 13

Leu Thr Ser Arg Leu Arg Phe Ile Pro
1 5

<210> 14

<211> 9

<212> PRT

<213> Homo sapiens

<400> 14

Leu Leu Thr Ser Arg Leu Arg Phe Ile
1 5

<210> 15

<211> 9

<212> PRT

<213> Homo sapiens

<400> 15

Ala Leu Leu Thr Ser Arg Leu Arg Phe
1 5

<210> 16

<211> 9

<212> PRT

<213> Homo sapiens

<400> 16

Pro Ala Leu Leu Thr Ser Arg Leu Arg
1 5

<210> 17

<211> 9

<212> PRT

<213> Homo sapiens

<400> 17

Arg Pro Ala Leu Leu Thr Ser Arg Leu
1 5

<210> 18

<211> 9

<212> PRT

<213> Homo sapiens

<400> 18

Ala Arg Pro Ala Leu Leu Thr Ser Arg
1 5

<210> 19

<211> 9

<212> PRT

<213> Homo sapiens

<400> 19

Glu Ala Arg Pro Ala Leu Leu Thr Ser
1 5

09743281B.0740501



ENTERED

PCT09

RAW SEQUENCE LISTING

DATE: 03/07/2002

PATENT APPLICATION: US/09/743,281B

TIME: 15:39:58

Input Set : A:\01702.401800.txt

Output Set: N:\CRF3\03072002\I743281B.raw

```

3 <110> APPLICANT: Gaudernack, Gustav
4   Eriksen, Jon Amund
5   Moller, Mona
6   Gjertsen, Marianne Klemp
7   Saeterdal, Ingvil
8   Saeboe-Larsen, Stein
10 <120> TITLE OF INVENTION: Antigenic Peptides Derived from Telomerase
12 <130> FILE REFERENCE: 1702.401800
14 <140> CURRENT APPLICATION NUMBER: US 09/743,281B
C--> 15 <141> CURRENT FILING DATE: 2002-02-20
17 <150> PRIOR APPLICATION NUMBER: PCT/NO99/00220
18 <151> PRIOR FILING DATE: 1999-06-30
20 <160> NUMBER OF SEQ ID NOS: 19
22 <170> SOFTWARE: PatentIn version 3.1
24 <210> SEQ ID NO: 1
25 <211> LENGTH: 22
26 <212> TYPE: PRT
27 <213> ORGANISM: Homo sapiens
29 <400> SEQUENCE: 1
31 Phe Leu His Trp Leu Met Ser Val Tyr Val Val Glu Leu Leu Arg Ser
32 1           5           10           15
35 Phe Phe Tyr Val Thr Glu
36           20
39 <210> SEQ ID NO: 2
40 <211> LENGTH: 16
41 <212> TYPE: PRT
42 <213> ORGANISM: Homo sapiens
44 <400> SEQUENCE: 2
46 Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg Phe Ile Pro Lys
47 1           5           10           15
50 <210> SEQ ID NO: 3
51 <211> LENGTH: 16
52 <212> TYPE: PRT
53 <213> ORGANISM: Homo sapiens
55 <400> SEQUENCE: 3
57 Asp Gly Leu Arg Pro Ile Val Asn Met Asp Tyr Val Val Gly Ala Arg
58 1           5           10           15
61 <210> SEQ ID NO: 4
62 <211> LENGTH: 18
63 <212> TYPE: PRT
64 <213> ORGANISM: Homo sapiens
66 <400> SEQUENCE: 4
68 Gly Val Pro Glu Tyr Gly Cys Val Val Asn Leu Arg Lys Thr Val Val

```

03/07/2002 15:39:58

RAW SEQUENCE LISTING

DATE: 03/07/2002

PATENT APPLICATION: US/09/743,281B

TIME: 15:39:58

Input Set : A:\01702.401800.txt

Output Set: N:\CRF3\03072002\I743281B.raw

```

69 1          5          10          15
72 Asn Phe
76 <210> SEQ ID NO: 5
77 <211> LENGTH: 23
78 <212> TYPE: PRT
79 <213> ORGANISM: Homo sapiens
81 <400> SEQUENCE: 5
83 Lys Phe Leu His Trp Leu Met Ser Val Tyr Val Val Glu Leu Leu Arg
84 1          5          10          15
87 Ser Phe Phe Tyr Val Thr Glu
88          20
91 <210> SEQ ID NO: 6
92 <211> LENGTH: 17
93 <212> TYPE: PRT
94 <213> ORGANISM: Homo sapiens
96 <400> SEQUENCE: 6
98 Lys Phe Leu His Trp Leu Met Ser Val Tyr Val Val Glu Leu Leu Arg
99 1          5          10          15
102 Ser
106 <210> SEQ ID NO: 7
107 <211> LENGTH: 18
108 <212> TYPE: PRT
109 <213> ORGANISM: Homo sapiens
111 <400> SEQUENCE: 7
113 Leu Met Ser Val Tyr Val Val Glu Leu Leu Arg Ser Phe Phe Tyr Val
114 1          5          10          15
117 Thr Glu
121 <210> SEQ ID NO: 8
123 <400> SEQUENCE: 8
W--> 124 000
127 <210> SEQ ID NO: 9
128 <211> LENGTH: 9
129 <212> TYPE: PRT
130 <213> ORGANISM: Homo sapiens
132 <400> SEQUENCE: 9
134 Ile Leu Ala Lys Phe Leu His Trp Leu
135 1          5
138 <210> SEQ ID NO: 10
139 <211> LENGTH: 9
140 <212> TYPE: PRT
141 <213> ORGANISM: Homo sapiens
143 <400> SEQUENCE: 10
145 Glu Leu Leu Arg Ser Phe Phe Tyr Val
146 1          5
149 <210> SEQ ID NO: 11
150 <211> LENGTH: 9
151 <212> TYPE: PRT
152 <213> ORGANISM: Homo sapiens
154 <400> SEQUENCE: 11

```

03743281B.03743281B

RAW SEQUENCE LISTING

DATE: 03/07/2002

PATENT APPLICATION: US/09/743,281B

TIME: 15:39:58

Input Set : A:\01702.401800.txt

Output Set: N:\CRF3\03072002\I743281B.raw

156 Leu Met Ser Val Tyr Val Val Glu Leu
157 1 5
160 <210> SEQ ID NO: 12
161 <211> LENGTH: 9
162 <212> TYPE: PRT
163 <213> ORGANISM: Homo sapiens
165 <400> SEQUENCE: 12
167 Thr Ser Arg Leu Arg Phe Ile Pro Lys
168 1 5
171 <210> SEQ ID NO: 13
172 <211> LENGTH: 9
173 <212> TYPE: PRT
174 <213> ORGANISM: Homo sapiens
176 <400> SEQUENCE: 13
178 Leu Thr Ser Arg Leu Arg Phe Ile Pro
179 1 5
182 <210> SEQ ID NO: 14
183 <211> LENGTH: 9
184 <212> TYPE: PRT
185 <213> ORGANISM: Homo sapiens
187 <400> SEQUENCE: 14
189 Leu Leu Thr Ser Arg Leu Arg Phe Ile
190 1 5
193 <210> SEQ ID NO: 15
194 <211> LENGTH: 9
195 <212> TYPE: PRT
196 <213> ORGANISM: Homo sapiens
198 <400> SEQUENCE: 15
200 Ala Leu Leu Thr Ser Arg Leu Arg Phe
201 1 5
204 <210> SEQ ID NO: 16
205 <211> LENGTH: 9
206 <212> TYPE: PRT
207 <213> ORGANISM: Homo sapiens
209 <400> SEQUENCE: 16
211 Pro Ala Leu Leu Thr Ser Arg Leu Arg
212 1 5
215 <210> SEQ ID NO: 17
216 <211> LENGTH: 9
217 <212> TYPE: PRT
218 <213> ORGANISM: Homo sapiens
220 <400> SEQUENCE: 17
222 Arg Pro Ala Leu Leu Thr Ser Arg Leu
223 1 5
226 <210> SEQ ID NO: 18
227 <211> LENGTH: 9
228 <212> TYPE: PRT
229 <213> ORGANISM: Homo sapiens
231 <400> SEQUENCE: 18

03/07/2002 15:39:58

RAW SEQUENCE LISTING

DATE: 03/07/2002

PATENT APPLICATION: US/09/743,281B

TIME: 15:39:58

Input Set : A:\01702.401800.txt

Output Set: N:\CRF3\03072002\I743281B.raw

233 Ala Arg Pro Ala Leu Leu Thr Ser Arg
234 1 5
237 <210> SEQ ID NO: 19
238 <211> LENGTH: 9
239 <212> TYPE: PRT
240 <213> ORGANISM: Homo sapiens
242 <400> SEQUENCE: 19
244 Glu Ala Arg Pro Ala Leu Leu Thr Ser
245 1 5

03072002.107050.1

VERIFICATION SUMMARY

PATENT APPLICATION: US/09/743,281B

DATE: 03/07/2002

TIME: 15:39:59

Input Set : A:\01702.401800.txt

Output Set: N:\CRF3\03072002\I743281B.raw

L:15 M:271 C: Current Filing Date differs, Replaced Current Filing Date

L:124 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (8) SEQUENCE:

00745009/743281

534 Rec'd PCT/PTO 08 JAN2001
PATENT APPLICATION

1702.401800

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
GUSTAV GAUDERNACK, ET AL.)	: Examiner: Unassigned
Int'l Appln. No.: PCT/NO99/00220)	: Group Art Unit: Unassigned
Int'l Publn. No.: WO 00/02581)	:
U.S. Appln. No.: Unassigned)	:
Nat'l Entry Date: January 8, 2001)	:
For: ANTIGENIC PEPTIDES DERIVED)	: January 8, 2001
FROM TELOMERASE)	:

Commissioner For Patents
Washington, D.C. 20231

STATEMENT UNDER 37 C.F.R. § 1.821(f)

Sir:

Applicants hereby submit that the sequence listing information recorded in computer readable form on the attached diskette is identical to the written sequence listing filed concurrently herewith.

Applicants' undersigned attorney may be reached in our Washington, D.C. office by telephone at (202) 530-1010. All correspondence should be directed to our address listed below.

Respectfully submitted,



John W. Behringer
Reg. No. 23,086
Attorney for Applicants

FITZPATRICK, CELLA, HARPER & SCINTO
30 Rockefeller Plaza
New York, New York, 10112-3801
Facsimile: (212) 218-2200

NMD\llp

09/743281 09/743281

09/743281

534 Rec'd PCT/PTC 08 JAN 2001

1702.401800

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
GUSTAV GAUDERNACK, ET AL.) : Examiner: Unassigned
Int'l Appln. No.: PCT/NO99/00220) : Group Art Unit: Unassigned
Int'l Publn. No.: WO 00/02581) :
U.S. Appln. No.: Unassigned) :
Nat'l Entry Date: January 8, 2001) :
For: ANTIGENIC PEPTIDES) January 8, 2001
DERIVED FROM TELOMERASE) :

Commissioner For Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Prior to the examination on the merits, please amend
The above-identified application as follows.

IN THE SPECIFICATION:

Please amend the specification as follows:

Page 1,

Line 8, change "recognising" to --recognizing--; and
change "tumour" to --tumor--;

Line 12, change "tumour" to --tumor--;
 Line 15, change "harbouring" to --harboring--;
 Line 20, change "Tumour-" to --Tumor- --;
 Line 21, change "i.e." to --i.e.,--; and
 Line 26, change "tumour-" to --tumor- --.

Page 2,

Line 1, change "are however" to --are, however,--;
 Line 2, change "immortalisation" to
 --immortalization--;
 Line 3, change "tumour" to --tumor--;
 Line 6, change "tumour" to --tumor--;
 Line 8, change "tumour" to --tumor--;
 Line 11, change "characterise" to --characterize--;
 Line 13, change "tumour" to --tumor--;
 Line 15, change "instance" to --instance,--;
 Line 17, change "tumour" to --tumor--;
 Line 18, change "tumour" to --tumor--;
 Line 29, change "recognise" to --recognize--;
 Line 30, change "recognise" to --recognize--; and
 Line 33, change "recognise" to --recognize--.

Page 3,

Line 3, change "recognise" to --recognize--;

Line 4, change "recognise" to --recognize--;

Line 5, change "tumour" to --tumor--;

Line 6, change "tumour" to --tumor--;

Line 7, change "tumour" to --tumor--; and change
"harbouring" to --harboring--;

Line 9, change "tumours" to --tumors--;

Line 10, change "tumour" to --tumor--;

Line 13, change "recognising" to --recognizing--;

Line 15, change "tumour" to --tumor-- (both occurrences); and

Line 16, change "tumour" to --tumor--.

Page 4,

Line 10, change "tumour" to --tumor-- (both occurrences).

Page 5,

Line 4, change "tumour" to --tumor--;

Line 7, change "tumour" to --tumor--;

Line 19, change "harbouring" to --harboring--;

Line 21, change "have shown" to --showed--;



Line 23, change "harbouring" to --harboring--;

Line 29, change "tumour" to --tumor--;

Line 32, change "tumours" to --tumors--; and

Line 33, change "tumour" to --tumor--.

Page 6,

Line 4, change "tumour" to --tumor--;

Line 5, change "tumour" to --tumor--;

Line 11, change "synthesised" to --synthesized--; and

Line 12, change "specialised" to --specialized--.

Page 7,

Line 14, change "tumour" to --tumor--; and change
"analysed" to --analyzed--; and

Line 21, change "stabilising" to --stabilizing--.

Page 8,

Line 24, change "invention" to --invention,--.

Page 9,

Line 5, change "invention" to --invention,--;

Line 9, change "tumour" to --tumor--;

Line 18, change "tumour" to --tumor--;



Line 26, change "a" to --an--; and

Line 28, change "recognising" to --recognizing--; and

change "tumour" to --tumor--.

Page 10,

Page 11,

Page 13,

Page 14,

Page 15,

Line 13, change "duplication" to --duplication,--.

Page 18,

Line 5, change "synthesised" to --synthesized--;

Line 14, change "analysed" to --analyzed--; and

Line 15, change "identify" to --identity--.

Page 19,

Line 1, change "harbouring" to --harboring--;

Line 5, change "tumour" to --tumor--;

Line 20, change "days" to --days,--;

Line 28, change "characterisation" to
--characterization--;

Line 31, change "tumour" to --tumor--; and

Line 32, change "tumour" to --tumor--.

Page 20,

Line 1, change "tumour" to --tumor--;

Line 3, change "recognised" to --recognized--;

Line 6, change "tumour" to --tumor--;

Line 18, change "tumour" to --tumor--;

Line 22, change "recognises" to --recognizes--; and

Line 32, change "tumour" to --tumor--.

Page 21,

Line 6, change "recognised" to --recognized--.

Page 22,

Line 3, change "Peptide sensitised" to --Peptide-sensitized--;

Line 17, after "as" insert --a--; and

Line 25, change "auatologous" to --autologous--.

Page 23,

Line 8, change "cells, thus" to --cells. Thus--.

Page 24,

Line 24, after "results" insert --also--.

Page 25,

Line 16, change "recognise" to --recognize--;

Line 18, change "recognise" to --recognize--; and

Line 19, change "co-cultureing" to --co-culturing--.

32. The pharmaceutical composition according to claim 31, wherein the composition is for the treatment or prophylaxis of cancer.

33. The pharmaceutical composition according to claim 32, wherein the cancer is selected from the group consisting of breast cancer, prostate cancer, pancreatic cancer, colorectal cancer, lung cancer, malignant melanoma, leukemias, lymphomas, ovarian cancer, cervical cancer and biliary tract carcinomas.

34. A pharmaceutical composition comprising at least one telomerase peptide according to claim 28, and a pharmaceutically acceptable carrier or diluent.

35. The pharmaceutical composition according to claim 34, wherein the composition is for the treatment or prophylaxis of cancer.

36. The pharmaceutical composition according to claim 35, wherein the cancer is selected from the group consisting of breast cancer, prostate cancer, pancreatic cancer, colorectal cancer, lung cancer, malignant melanoma, leukemias, lymphomas, ovarian cancer, cervical cancer and biliary tract carcinomas.

37. A method of preparing a pharmaceutical composition, comprising the step of mixing at least one telomerase peptide of claim 28 with a pharmaceutically acceptable carrier or diluent.

38. A method of preparing a pharmaceutical composition, comprising the step of mixing at least one nucleic acid of claim 30 with a pharmaceutically acceptable carrier or diluent.

39. A pharmaceutical composition comprising:
 (a) at least one telomerase peptide according to claim 28,
 (b) at least one peptide capable of inducing a T cell response directed against either (i) an oncogene protein or peptide, or (ii) a mutant tumor suppressor protein or peptide, and

(c) a pharmaceutically acceptable carrier or diluent.

40. A method of preparing a pharmaceutical composition, comprising the step of forming a mixture of:

(a) at least one telomerase peptide according to claim 28,
 (b) at least one peptide capable of inducing a T cell response directed against either (i) an oncogene protein or peptide or (ii) a mutant tumor suppressor protein or peptide, and
 (c) a pharmaceutically acceptable carrier or diluent.

41. The pharmaceutical composition according to claim 39, wherein the oncogene protein or peptide is a mutant p21-ras protein or peptide, and the tumor suppressor protein or peptide is selected from the group consisting of a retinoblastoma protein or peptide and a p53 protein or peptide.

42. The method of preparing a pharmaceutical composition according to claim 40, wherein the oncogene protein or peptide is a mutant p21-ras protein or peptide, and the tumor suppressor protein or peptide is selected from the group consisting of a retinoblastoma protein or peptide and a p53 protein or peptide.

43. A method of generating T lymphocytes capable of recognizing and destroying tumor cells in a mammal, comprising the steps of:

- (a) taking a sample of T lymphocytes from a mammal, and
- (b) culturing the T lymphocyte sample in the presence of an amount of a telomerase peptide sufficient to generate telomerase-specific T lymphocytes, wherein the telomerase peptide comprises an amino acid residue sequence selected from the group consisting of: EARPALLTSRLRFIPK (SEQ ID NO: 2), DGLRPIVNMDYVVGAR (SEQ ID NO: 3), GVPEYGCVVNLRKTVVNF (SEQ ID NO: 4), ILAKFLHWL (SEQ ID NO: 9),

ELLRSFFYV (SEQ ID NO: 10), LMSVYVVELLRSFFYVTE (SEQ ID NO: 7), and the sequences set out in Table 1 and Table 2 herein.

44. A telomerase-specific T lymphocyte generated by the method according to claim 43.

45. A pharmaceutical composition comprising a telomerase-specific T lymphocyte according to claim 44, and a pharmaceutically acceptable carrier or diluent.

46. The pharmaceutical composition according to claim 45, wherein the composition is for the treatment or prophylaxis of cancer.

47. The pharmaceutical composition according to claim 46, wherein the cancer is selected from the group consisting of breast cancer, prostate cancer, pancreatic cancer, colorectal cancer, lung cancer, malignant melanoma, leukemias, lymphomas, ovarian cancer, cervical cancer and biliary tract carcinomas.

48. A method of treating a mammalian patient afflicted with cancer, comprising the step of administering to the patient an

effective amount of the pharmaceutical composition according to any one of claims 31, 34, 39 or 45.

49. The method of treatment according to claim 48, wherein the cancer is selected from the group consisting of breast cancer, prostate cancer, pancreatic cancer, colorectal cancer, lung cancer, malignant melanoma, leukemias, lymphomas, ovarian cancer, cervical cancer and biliary tract carcinomas.

50. The method of treatment according to claim 48, wherein the cancer is colon cancer.

51. A method of vaccinating a mammalian patient in order to obtain resistance against cancer comprising the step of eliciting a T-cell response in the patient by stimulating the patient's immune system *in vivo* or *ex vivo* with a telomerase peptide according to claim 28.--.

REMARKS

Applicants request early examination on the merits and favorable consideration of this application.

Claims 28-51 are presently pending in this application, with claims 28 and 43 being independent. Claims 1-27 as

originally filed in the parent PCT application (i.e., International Application No. PCT/NO99/00220 (or International Publication No. WO 00/02581)) have been cancelled without prejudice to or disclaimer of the subject matter recited in those claims.

Applicants believe that no new matter has been added by these claim amendments. Claims 28-51 have been drafted to be in better form under U.S. practice compared to claims previously pending in this application during international prosecution. Claims 28-51, for example, avoid improper multiple dependent claims and other objectionable claim forms.

Newly added claims 28-51 supercede not only originally-filed claims 1-27 but also claims 1-23 that were proposed during international prosecution by way of an amendment made pursuant to Art. 19 of the Patent Cooperation Treaty (PCT). A copy of these claims are enclosed. These same claims 1-23 were proposed again during international preliminary examination of the parent PCT application pursuant to Article 34 of the PCT and are also superceded by newly added claims 28-51. A copy of the Article 34 claim amendments is annexed to the International Preliminary Examination Report that is being submitted herewith.

The specification also has been amended to correct obvious typographical errors. For example, Applicants have

corrected the spelling of certain words, such that the National Phase application uses an American English lexicon, rather than a British English lexicon. Applicants submit that no new matter has been added by these specification amendments.

Applicants' undersigned attorney may be reached in our Washington, D.C. office by telephone at (202) 530-1010. All correspondence should be directed to our address listed below.

Respectfully submitted,



John W. Behringer
Reg. No. 23,086
Attorney for Applicants

FITZPATRICK, CELLA, HARPER & SCINTO
30 Rockefeller Plaza
New York, New York, 10112-3801
Facsimile: (212) 218-2200
JWB\NMD\llp

ANTIGENIC PEPTIDES DERIVED FROM TELOMERASE

This invention relates to proteins or peptides which elicit T cell mediated immunity, and to cancer vaccines and compositions for anti-cancer treatment comprising such proteins or peptide fragments. This invention also relates to pharmaceutical compositions comprising the proteins or peptides and methods for generating T lymphocytes capable of recognising and destroying tumour cells in a mammal.

Cancer develops through a multistep process involving several mutational events. These mutations result in altered expression/function of genes belonging to two categories: oncogenes and tumour suppressor genes. Oncogenes arise in nature from proto-oncogenes through point mutations or translocations, thereby resulting in a transformed state of the cell harbouring the mutation. All oncogenes code for and function through a protein. Proto-oncogenes are normal genes of the cell which have the potential of becoming oncogenes. In the majority of cases, proto-oncogenes have been shown to be components of signal transduction pathways. Oncogenes act in a dominant fashion. Tumour-suppressor genes on the other hand, act in a recessive fashion, i.e. through loss of function, and contribute to oncogenesis when both alleles encoding the functional protein have been altered to produce non-functional gene products.

The concerted action of a combination of altered oncogenes and tumour-suppressor genes results in cellular transformation and development of a malignant phenotype.

Such cells are however prone to senescence and have a limited life-span. In the majority of cancers, immortalisation of the tumour cells requires the turning on of an enzyme complex called telomerase. In somatic cells the catalytic subunit of this enzyme is normally not expressed. Additional events, such as the action of proteins encoded by a tumour virus or demethylation of silenced promoter sites can result in expression of a functional telomerase complex in tumour cells.

In the field of human cancer immunology, the last two decades have seen intensive efforts to characterise genuine cancer specific antigens. In particular, effort has been devoted to the analysis of antibodies to human tumour antigens. The prior art suggests that such antibodies can be used for diagnostic and therapeutic purposes, for instance in connection with an anti-cancer agent. However, antibodies can only bind to tumour antigens that are exposed on the surface of tumour cells. For this reason, the efforts to produce a cancer treatment based on the immune system of the body has been less successful than expected.

A fundamental feature of the immune system is that it can distinguish self from nonself and does not normally react against self molecules. It has been shown that rejection of tissues or organs grafted from other individuals is an immune response to the foreign antigens on the surface of the grafted cells. The immune response in general consists of a humeral response, mediated by antibodies, and a cellular response. Antibodies are produced and secreted by B lymphocytes, and typically recognise free antigen in native conformation. They can therefore potentially recognise almost any site exposed on the antigen surface. In contrast to antibodies, T cells, which mediate the cellular arm of the immune response, recognise antigens only in the context of MHC molecules, and only after appropriate antigen processing. This antigen processing usually consists of proteolytic

fragmentation of the protein, resulting in peptides that fit into the groove of the MHC molecules. This enables T cells to also recognise peptides derived from intracellular antigens.

T cells can recognise aberrant peptides derived from anywhere in the tumour cell, in the context of MHC molecules on the surface of the tumour cell. The T cells can subsequently be activated to eliminate the tumour cell harbouring the aberrant peptide. In experimental models involving murine tumours it has been shown that point mutations in intracellular "self" proteins may give rise to tumour rejection antigens, consisting of peptides differing in a single amino acid from the normal peptide. The T cells recognising these peptides in the context of the major histocompatibility (MHC) molecules on the surface of the tumour cells are capable of killing the tumour cells and thus rejecting the tumour from the host (Boon et al., 1989, Cell 58, 293-303).

MHC molecules in humans are normally referred to as HLA (human leucocyte associated antigen) molecules. There are two principal classes of HLA molecules, class I and class II. HLA class I molecules are encoded by HLA A, B and C subloci and primarily activate CD8+ cytotoxic T cells. HLA class II molecules, on the other hand, primarily activate CD4+ T cells, and are encoded by the DR, DP and DQ subloci. Every individual normally has six different HLA class I molecules, usually two alleles from each of the three subgroups A, B and C, although in some cases the number of different HLA class I molecules is reduced due to the occurrence of the same HLA allele twice.

The HLA gene products are highly polymorphic. Different individuals express distinct HLA molecules that differ from those found in other individuals. This explains the difficulty of finding HLA matched organ donors in transplantations. The significance of the genetic variation

of the HLA molecules in immunobiology is reflected by their role as immune-response genes. Through their peptide binding capacity, the presence or absence of certain HLA molecules governs the capacity of an individual to respond to specific peptide epitopes. As a consequence, HLA molecules determine resistance or susceptibility to disease.

T cells may inhibit the development and growth of cancer by a variety of mechanisms. Cytotoxic T cells, both HLA class I restricted CD8+ and HLA class II restricted CD4+ may directly kill tumour cells presenting the appropriate tumour antigens. Normally, CD4+ helper T cells are needed for cytotoxic CD8+ T cell responses, but if the peptide antigen is presented by an appropriate APC, cytotoxic CD8+ T cells can be activated directly, which results in a quicker, stronger and more efficient response.

While the peptides that are presented by HLA class II molecules are of varying length (12-25 amino acids), the peptides presented by HLA class I molecules must normally be exactly nine amino acid residues long in order to fit into the class I HLA binding groove. A longer peptide will result in non-binding if it cannot be processed internally by an APC or target cell, such as a cancer cell, before presenting in the class I HLA groove. Only a limited number of deviations from this requirement of nine amino acids have been reported, and in those cases the length of the presented peptide has been either eight or ten amino acid residues long.

Reviews of how MHC binds peptides can be found in Hans-Georg Rammensee, Thomas Friede and Stefan Stevanovic, (1995, Immunogenetics, 41, 178-228) and in Barinaga (1992, Science 257, 880-881). Male et al (1987, Advanced Immunology, J.B. Lippincott Company, Philadelphia) offers a more comprehensive explanation of the technical background to this invention.

strength of a cancer vaccine will increase with the number of targets that the vaccine is able to elicit T cell immunity against. A multiple target vaccine will also reduce the risk of new tumour formation by treatment escape variants from the primary tumour.

The enzyme telomerase has recently been the focus of attention for its supposed role in prevention of cellular ageing. Telomerase is a RNA-dependent DNA polymerase, which synthesises telomeric DNA repeats using an RNA template that exists as a subunit of the telomerase holoenzyme. The DNA repeats synthesised by the enzyme are incorporated into telomeres, which are specialised DNA-protein structures found at the ends of the linear DNA molecules which make up every chromosome. Telomerase was first identified in the ciliate *Tetrahymena* (Greider and Blackburn, 1985, *Cell* 43, 405-413). A human telomerase catalytic subunit sequence was recently identified by Meyerson et al (1990, *Cell* 1197, 785-795), and Nakamura et al (1997, *Science* 277, 955-959), who respectively named the gene hEST2 and hTERT. In addition, three other proteins which are associated with telomerase activity have also been identified: p80 and p95 of *Tetrahymena* (Collins et al, 1995, *Cell* 81, 677-686) and TP1/TLP1, which is the mammalian homologue of *Tetrahymena* p80 (Harrington et al, 1997, *Science*, 275, 973-977; Nakayama et al., 1997, *Cell* 88, 875-884).

Telomerase is not expressed in most normal cells in the body. Most somatic lineages in humans show no detectable telomerase activity, but telomerase activity is detected the germline and in some stem cell compartments, which are sites of active cell division (Harley et al., 1994, *Cold Spring Harbor Symp. Quant. Biol.* 59, 307-315; Kim et al., 1994, *Science* 266, 2011-2015; Broccoli et al, 1995, *PNAS USA* 92, 9082-9086; Counter et al., 1995, *Blood* 85, 2315-2320; Hiyama et al., 1995, *J. Immunol.* 155, 3711-3715). Telomeres of most types of

human somatic cells shorten with increasing age of the organism, consistent with lack of telomerase activity in these cells. Cultured human cells also show telomere shortening. Telomere shortening continues in cultured human cells which have been transformed, until the telomeres have become critically short. At this point, termed the crisis point, significant levels of cell death and karyotypic instability are observed.

Immortal cells, which have acquired the ability to grow indefinitely in culture, emerge at rare frequency from crisis populations. These immortal cells have high levels of telomerase activity and stable telomeres. Telomerase activity is also readily detected in the great majority of human tumour samples analysed to date (Kim et al, 1994, *Science* 266, 2011-2015), including ovarian carcinoma (Counter et al., 1994, *PNAS USA* 91, 2900-2904). A comprehensive review is provided by Shay and Bachetti (1997, *Eur. J. Cancer* 33, 787-791). Thus, activation of telomerase may overcome the barriers to continuous cell division imposed by telomere length. Cells that overcome the normal senescence mechanisms may do so by stabilising telomere length, probably due to the activity of telomerase.

Viruses implicated in human cancer development such as Epstein Barr virus (EBV, related to B cell malignancies and nasopharyngeal carcinomas) and Human Papilloma virus (HPV 16 and 18, related to cervical carcinomas) have long been known to have the capacity to immortalize human cells. It has now been demonstrated that induction of telomerase activity is the key element in this process (Klingelutz et al, 1996, *Nature*, 380, 79-82).

Telomerase is therefore a potential target for cancer therapy. Thus, telomerase inhibitors have been proposed as a new class of anti-cancer drugs (reviewed in Sharma et al,

1997, *Ann Oncol* 8(11), 1063-1074; Axelrod, 1996, *Nature Med* 2(2), 158-159; Huminiecki, 1996, *Acta Biochim Pol*, 43(3), 531-538). It has been suggested that the identification of a human telomerase catalytic subunit may provide a biochemical reagent for identifying such drugs (Meyerson et al, 1990, *Cell* 1197, 785-795). Telomerase has also been suggested to be a marker for diagnosis or prognosis of cancer (Soria and Rixe, 1997, *Bull Cancer* 84(10), 963-970; Dahse et al, 1997, *Clin Chem* 43(5), 708-714).

As far as we are aware, however, no one has previously suggested that telomerase may function as a useful target for T cell mediated therapy, or that telomerase peptides or proteins may be used for the treatment or prophylaxis of cancer.

In accordance with one aspect of the invention, we provide a telomerase protein or peptide for use in a method of treatment or prophylaxis of cancer.

In accordance with a second aspect of the invention, there is provided a nucleic acid for use in a method of treatment or prophylaxis of cancer, the nucleic acid being capable of encoding a telomerase protein or peptide as provided in the first aspect of this invention.

We provide, in accordance with a third aspect of this invention a pharmaceutical composition comprising at least one telomerase protein or peptide or nucleic acid as provided in the first or second aspect of this invention and a pharmaceutically acceptable carrier or diluent.

According to a fourth aspect of this invention, we provide a method for the preparation of a pharmaceutical composition as provided in the third aspect of the invention, the method comprising mixing at least one telomerase protein or peptide

or nucleic acid as provided in the first or second aspect of the invention with a pharmaceutically acceptable carrier or diluent.

There is further provided, according to a fifth aspect of this invention a pharmaceutical composition comprising a combination of at least one telomerase protein or peptide as provided in the first aspect of this invention and at least one peptide capable of inducing a T cell response against an oncogene or mutant tumour suppressor protein or peptide, together with a pharmaceutically acceptable carrier or diluent.

We further provide, in accordance with a sixth aspect of this invention, a method for the preparation of a pharmaceutical composition as provided in the fifth aspect of this invention, the method comprising mixing at least one telomerase protein or peptide provided in the first aspect of this invention, with at least one peptide capable of inducing a T cell response against an oncogene or tumour suppressor protein or peptide, and a pharmaceutically acceptable carrier or diluent.

In accordance with a seventh aspect of this invention, we provide the use, in the preparation of a medicament for the treatment or prophylaxis of cancer, of a telomerase protein or peptide, or a nucleic acid capable of encoding a telomerase protein or peptide.

According to a eighth aspect of this invention, there is provided a method of generating T lymphocytes capable of recognising and destroying tumour cells in a mammal, comprising taking a sample of T lymphocytes from a mammal, and culturing the T lymphocyte sample in the presence of telomerase protein or peptide in an amount sufficient to generate telomerase protein or peptide specific T lymphocytes.

The invention is more particularly described, by way of example only, with reference to the accompanying drawing, in which:

FIGURE 1 shows the sequences of the conserved amino acid motifs in the human telomerase catalytic subunit, as identified by Meyerson et al (1997, Cell 90, 785-795) and Nakamura et al (1997 Science 277, 955-959). Motifs T, 1, 2, 3 (A of Nakamura), 4 (B' of Nakamura) 5 (C of Nakamura), 6 (D of Nakamura) and E are shown. Peptides may be synthesised with sequences corresponding to or encompassing any of the bracketed regions. The designations A2, A1, A3 and B7 indicate peptides which are likely to be presented by HLA-A2, HLA-A1, HLA-A3 and HLA-B7 respectively.

We provide a telomerase protein or peptide for use in a method of treatment or prophylaxis of cancer. In a preferred embodiment, the method comprises generating a T cell response against telomerase. The method may comprise administering to a mammal, preferably a human, suffering or likely to suffer from cancer a therapeutically effective amount of the telomerase protein or peptide so that a T cell response against the telomerase is induced in the mammal.

Telomerase specific T cells may be used to target cells which express telomerase. Thus, since most cells in the body of an organism do not express telomerase, they will be unaffected. However, tumour cells that express telomerase will be targeted and destroyed. As telomerase activity has been detected in the majority of cancers identified so far, we expect our materials and methods to have widespread utility.

Cancers which are suitable for treatment include, but are not limited to, breast cancer, prostate cancer, pancreatic cancer, colo-rectal cancer, lung cancer, malignant melanoma,

leukaemias, lymphomas, ovarian cancer, cervical cancer and biliary tract carcinomas.

As used here, the term telomerase denotes a ribonucleoprotein enzyme which has telomere elongating activity. Telomerase protein as used here denotes any protein component of telomerase, including any subunit having catalytic activity.

Preferably the telomerase protein is a mammalian telomerase protein, and most preferably a human telomerase protein. The human telomerase protein is preferably the telomerase catalytic subunit identified as hTRT by Nakamura et al (1997, *Science* 277, 955-959) and hEST2 by Meyerson et al (1990, *Cell* 1197, 785-795), the cDNA sequences of which are deposited as GenBank accession numbers AF015950 and AF018167 respectively.

The term telomerase peptide as used here means a peptide which has an amino acid sequence corresponding to a sequence present in the amino acid sequence of a telomerase protein. The telomerase peptides preferably contain between 8 and 25 amino acids. More preferably, the telomerase peptides contain between 9 and 25 amino acids. For instance, the telomerase peptides contain 9, 12, 13, 16 or 21 amino acids.

The telomerase protein or peptide is chosen so that it is capable of generating a T cell response directed against the telomerase protein (or against the telomerase protein from which the telomerase peptide is derived). In preferred embodiments, the T cell response induced is a cytotoxic T cell response. The cytotoxic T cell response may be a CD4+ T cell response, or it may be a CD8+ T cell response. In any case, the peptide must be capable of being presented as a complex with a MHC class I or class II protein on the surface of tumour cells or antigen presenting cells, with antigen processing taking place beforehand if necessary.

The telomerase peptide may include one or more amino acid residues from an amino acid motif essential for the biological function of the telomerase protein; in other words, it may overlap at least partially with such an amino acid motif. Examples of such amino acid motifs are motifs 1 to 6 of the human telomerase catalytic subunit sequence hEST2 as identified by Meyerson et al (1990, *Cell* 1197, 785-795), in other words, from the motifs

LLRSFFYVTE
SRLRFIPK,
LRPIVNMDYVVG,
PELYFVKVDVTGAYDTI,
KSYVQCQGIPQGSILSTLLCSLCY,
LLLRLVDDFLLVT and
GCVVNLRKTVV

or from any of motifs T, 1, 2, A, B', C, D or E as identified by Nakamura et al (1997, *Science* 277, 955-959) in the hTRT sequence, namely, the motifs

WLMSVYVVELLRSFFYVTETTFQKNRLFFYRKSVWSKLQSIGIRQHLK,
EVRQHREARPALLTSRLRFIPKPDG,
LRPIVNMDYVVGARTFRREKRAERLTSRV,
PPPELYFVKVDVTGAYDTIPQDRLTEVIASIIKP,
KSYVQCQGIPQGSILSTLLCSLCYGD MENKLFAGI,
LLLRLVDDFLLVTPHLTH,
AKTFLRTLVRGVPEYGCVVNLRKTVV and HGLFPWCGLLL.

Suitable peptides which may be used in the methods and compositions described here are set out in TABLE 1 as well as in the attached sequence identity list.

Another set of suitable peptides derived from elsewhere in the telomerase sequence, which may be used in the methods and compositions described here, are set out in TABLE 2.

Also included are proteins and peptides having amino acid sequences corresponding to an amino acid sequence present in

the amino acid sequence of mammalian homologues of the *Tetrahymena* telomerase associated proteins p80 and p95. For example, the p80 homologues TP1 and TLP1 (Harrington et al, 1997, *Science*, 275, 973-977; Nakayama et al., 1997, *Cell* 88, 875-884).

Larger peptide fragments carrying a few amino acid substitutions at either the N-terminal end or the C-terminal end are also included, as it has been established that such peptides may give rise to T cell clones having the appropriate specificity.

The peptides described here are particularly suited for use in a vaccine capable of safely eliciting either CD4+ or CD8+ T cell immunity:

- a) the peptides are synthetically produced and therefore do not include transforming cancer genes or other sites or materials which might produce deleterious effects,
- (b) the peptides may be used alone to induce cellular immunity,
- (c) the peptides may be targeted for a particular type of T cell response without the side effects of other unwanted responses.

The telomerase peptides or proteins described here can be administered in an amount in the range of 1 microgram (1µg) to 1 gram (1g) to an average human patient or individual to be vaccinated. It is preferred to use a smaller dose in the range of 1 microgram (1µg) to 1 milligram (1mg) for each administration.

In preferred embodiments, the telomerase protein or peptide is provided to the patient in the form of a pharmaceutical composition. The telomerase protein or peptide may be administered as a mixture of proteins or a mixture of proteins and peptides or a mixture of peptides. The

pharmaceutical composition may in addition include the usual additives, diluents, stabilisers or the like as known in the art.

The pharmaceutical composition may comprise one or more telomerase proteins or peptides. The protein or peptide mixture may be any one of the following:

- (a) a mixture of peptides having different sequences, for example, corresponding to different portions of a telomerase protein sequence;
- (b) a mixture of peptides having overlapping sequences, but suitable to fit different HLA alleles;
- (c) a mixture of both mixtures (a) and (b);
- (d) a mixture of several mixtures (a);
- (e) a mixture of several mixtures (b);
- (f) a mixture of several mixtures (a) and several mixtures (b);

In each case, a mixture of proteins or peptides corresponding to different telomerase proteins, for example, a telomerase catalytic subunit and a *Tetrahymena* p80 or p95 homologue, may also be used.

Alternatively, the telomerase peptides in the mixture may be covalently linked with each other to form larger polypeptides or even cyclic polypeptides. The pharmaceutical composition may be made by mixing the telomerase protein(s) or peptide(s) with a pharmaceutically acceptable carrier or diluent.

The pharmaceutical composition may also include at least one peptide capable of inducing a T cell response against an oncogene or mutant tumour suppressor protein or peptide. Alternatively, the telomerase proteins or peptides may be administered either simultaneously or in optional sequence with these peptides. Examples of oncogene proteins are the p21-ras proteins H-ras, K-ras and N-ras, abl, gip, gsp, ret

and trk. Preferably, the oncogene protein or peptide is a p21-ras protein or peptide, for example, the p21-ras peptides described in our International Application PCT/NO92/00032 (publication number WO92/14756). Tumour suppressor proteins include p53 and Rb (retinoblastoma). Such a pharmaceutical composition may be made by mixing the telomerase protein(s) or peptide(s) with the mutant tumour suppressor or oncogene proteins or peptides, together with a pharmaceutically acceptable carrier or diluent.

As used here, the term mutant refers to a wild type sequence which has one or more of the following: point mutation (transition or transversion), deletion, insertion, duplication translocation or inversion. The term pharmaceutical composition not only encompasses a composition usable in treatment of cancer patients, but also includes compositions useful in connection with prophylaxis, i.e., vaccine compositions.

The telomerase peptides or proteins are administered to a human individual in need of such treatment or prophylaxis. The administration may take place one or several times as suitable to establish and/or maintain the wanted T cell immunity. The peptides may be administered together, either simultaneously or separately, with compounds such as cytokines and/or growth factors, i.e., interleukin-2 (IL-2), interleukin-12 (IL-12), granulocyte macrophage colony stimulating factor (GM-CSF) or the like in order to strengthen the immune response as known in the art. The telomerase proteins or peptides can be used in a vaccine or a therapeutical composition either alone or in combination with other materials. For example, the peptide or peptides may be supplied in the form of a lipopeptide conjugate which is known to induce a high-affinity cytotoxic T cell response (Deres, 1989, *Nature* 342).

The peptides and proteins mentioned above as possible constituents of the pharmaceutical composition may be provided in the form of nucleic acid encoding the particular peptide or protein. Thus, the pharmaceutical composition may consist of peptide and/or protein alone, or in combination with nucleic acid, or it may consist of mixtures of nucleic acids.

The telomerase peptides or proteins may be administered to an individual in the form of DNA vaccines. The DNA encoding the telomerase peptide or protein may be in the form of cloned plasmid DNA or synthetic oligonucleotide. The DNA may be delivered together with cytokines, such as IL-2, and/or other co-stimulatory molecules. The cytokines and/or co-stimulatory molecules may themselves be delivered in the form of plasmid or oligonucleotide DNA.

The response to a DNA vaccine has been shown to be increased by the presence of immunostimulatory DNA sequences (ISS). These can take the form of hexameric motifs containing methylated CpG, according to the formula :

5'-purine-purine-CG-pyrimidine-pyrimidine-3'. Our DNA vaccines may therefore incorporate these or other ISS, in the DNA encoding the telomerase peptide or protein, in the DNA encoding the cytokine or other co-stimulatory molecules, or in both. A review of the advantages of DNA vaccination is provided by Tighe et al (1998, *Immunology Today*, 19(2), 89-97).

We describe a method of treatment of a patient afflicted with cancer, the method comprising eliciting T-cell responses through stimulating *in vivo* or *ex vivo* with a telomerase protein or peptide. The telomerase protein or peptide can also be used in a method of vaccination of a patient in order to obtain resistance against cancer. A suitable method of vaccination comprises eliciting T-cell responses through

stimulating *in vivo* or *ex vivo* with a telomerase protein or peptide. We also describe a method of treatment or prophylaxis of cancer, comprising administering to a mammal suffering or likely to suffer from cancer a therapeutically effective amount of a telomerase protein or peptide so that a T cell response against telomerase is induced in the mammal.

The peptides described here may be produced by conventional processes, for example, by the various peptide synthesis methods known in the art. Alternatively, they may be fragments of a telomerase protein produced by cleavage, for example, using cyanogen bromide, and subsequent purification. Enzymatic cleavage may also be used. The telomerase proteins or peptides may also be in the form of recombinant expressed proteins or peptides.

Nucleic acids encoding the telomerase peptide can be made by oligonucleotide synthesis. This may be done by any of the various methods available in the art. A nucleic acid encoding telomerase protein may be cloned from a genomic or cDNA library, using conventional library screening. The probe may correspond to a portion of any sequence of a known telomerase gene. Alternatively, the nucleic acid can be obtained by using the Polymerase Chain Reaction (PCR). The nucleic acid is preferably DNA, and may suitably be cloned into a vector. Subclones may be generated by using suitable restriction enzymes. The cloned or subcloned DNA may be propagated in a suitable host, for example a bacterial host. Alternatively, the host can be a eukaryotic organism, such as yeast or baculovirus. The telomerase protein or peptides may be produced by expression in a suitable host. In this case, the DNA is cloned into an expression vector. A variety of commercial expression kits are available. The methods described in Maniatis et al (1991, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor, New York, Cold Spring Harbor Laboratory Press) and Harlow and Lane (1988,

Antibodies: A Laboratory Manual, Cold Spring Harbor, New York, Cold Spring Harbor Laboratory Press) may be used for these purposes.

Experimental Methods

The peptides were synthesised by using continuous flow solid phase peptide synthesis. N- α -Fmoc-amino acids with appropriate side chain protection were used. The Fmoc-amino acids were activated for coupling as pentafluorophenyl esters or by using either TBTU or diisopropyl carbodiimide activation prior to coupling. 20% piperidine in DMF was used for selective removal of Fmoc after each coupling. Cleavage from the resin and final removal of side chain protection was performed by 95% TFA containing appropriate scavengers. The peptides were purified and analysed by reversed phase (C18) HPLC. The identify of the peptides was confirmed by using electro-spray mass spectroscopy (Finnigan mat SSQ710).

In order for a cancer vaccine and methods for specific cancer therapy based on T cell immunity to be effective, three conditions must be met:

- (a) the peptide is at least 8 amino acids long and is a fragment of a telomerase protein and
- (b) the peptide is capable of inducing, either in its full length or after processing by antigen presenting cell, T cell responses.

The following experimental methods may be used to determine if these three conditions are met for a particular peptide. First, it should be determined if the particular peptide gives rise to T cell immune responses *in vitro*. It will also need to be established if the synthetic peptides correspond to, or are capable after processing to yield, peptide fragments corresponding to peptide fragments occurring in

cancer cells harbouring telomerase or antigen presenting cells that have processed naturally occurring telomerase. The specificity of T cells induced *in vivo* by telomerase peptide vaccination may also be determined.

It is necessary to determine if telomerase expressing tumour cell lines can be killed by T cell clones obtained from peripheral blood from carcinoma patients after telomerase peptide vaccination. T cell clones are obtained after cloning of T-cell blasts present in peripheral blood mononuclear cells (PBMC) from a carcinoma patient after telomerase peptide vaccination. The peptide vaccination protocol includes several *in vivo* injections of peptides intracutaneously with GM-CSF or another commonly used adjuvant. Cloning of T cells is performed by plating responding T cell blasts at 5 blasts per well onto Terasaki plates. Each well contains 2×10^4 autologous, irradiated (30 Gy) PBMC as feeder cells. The cells are propagated with the candidate telomerase peptide at 25 mM and 5 U/ml recombinant interleukin-2 (rIL-2) (Amersham, Aylesbury, UK) in a total volume of 20 mL. After 9 days T cell clones are transferred onto flat-bottomed 96-well plates (Costar, Cambridge, MA) with 1 mg/ml phytohemagglutinin (PHA, Wellcome, Dartford, UK), 5 U/ml rIL-2 and allogenic irradiated (30 Gy) PBMC (2×10^5) per well as feeder cells. Growing clones are further expanded in 24-well plates with PHA / rIL-2 and 1×10^6 allogenic, irradiated PBMC as feeder cells and screened for peptide specificity after 4 to 7 days.

T cell clones are selected for further characterisation. The cell-surface phenotype of the T cell clone is determined to ascertain if the T cell clone is CD4+ or CD8+. T cell clone is incubated with autologous tumour cell targets at different effector to target ratios to determine if lysis of tumour cells occurs. Lysis indicates that the T cell has reactivity

directed against a tumour derived antigen, for example, telomerase protein.

In order to verify that the antigen recognised is associated with telomerase protein, and to identify the HLA class I or class II molecule presenting the putative telomerase peptide to the T cell clone, different telomerase expressing tumour cell lines carrying one or more HLA class I or II molecules in common with those of the patient are used as target cells in cytotoxicity assays. Target cells are labelled with ^{51}Cr or ^3H -thymidine (9.25×10^4 Bq/mL) overnight, washed once and plated at 5000 cells per well in 96 well plates. T cells are added at different effector to target ratios and the plates are incubated for 4 hours at 37°C and then harvested before counting in a liquid scintillation counter (Packard Topcount). For example, the bladder carcinoma cell line T24 (12Val $^+$, HLA-A1 $^+$, B35 $^+$), the melanoma cell line FMEX (12Val $^+$, HLA-A2 $^+$, B35 $^+$) and the colon carcinoma cell line SW 480 (12Val $^+$, HLA-A2 $^+$, B8 $^+$) or any other telomerase positive tumour cell line may be used as target cells. A suitable cell line which does not express telomerase protein may be used as a control, and should not be lysed. Lysis of a particular cell line indicates that the T cell clone being tested recognises an endogenously-processed telomerase epitope in the context of the HLA class I or class II subtype expressed by that cell line.

The HLA class I or class II restriction of a T cell clone may be determined by blocking experiments. Monoclonal antibodies against HLA class I antigens, for example the panreactive HLA class I monoclonal antibody W6/32, or against class II antigens, for example, monoclonals directed against HLA class II DR, DQ and DP antigens (B8/11, SPV-L3 and B7/21), may be used. The T cell clone activity against the autologous tumour cell line is evaluated using monoclonal antibodies directed against HLA class I and class II molecules at a final concentration of 10 mg/ml. Assays are set up as described

above in triplicate in 96 well plates and the target cells are preincubated for 30 minutes at 37°C before addition of T cells.

The fine specificity of a T cell clone may be determined using peptide pulsing experiments. To identify the telomerase peptide actually being recognised by a T cell clone, a panel of nonamer peptides is tested. ⁵¹Cr or ³H-thymidine labelled, mild acid eluted autologous fibroblasts are plated at 2500 cells per well in 96 well plates and pulsed with the peptides at a concentration of 1 mM together with b2-microglobulin (2.5 mg/mL) in a 5% CO₂ incubator at 37°C before addition of the T cells. Assays are set up in triplicate in 96 well plates and incubated for 4 hours with an effector to target ratio of 5 to 1. Controls can include T cell clone cultured alone, with APC in the absence of peptides or with an irrelevant melanoma associated peptide MART-1/Melan-A peptide.

An alternative protocol to determine the fine specificity of a T cell clone may also be used. In this alternative protocol, the TAP deficient T2 cell line is used as antigen presenting cells. This cell line expresses only small amounts of HLA-A2 antigen, but increased levels of HLA class I antigens at the cell surface can be induced by addition of b2-microglobulin. ³H-labelled target cells are incubated with the different test peptides and control peptides at a concentration of 1 mM together with b2-microglobulin (2.5 mg/mL) for one hour at 37°C. After peptide pulsing, the target cells are washed extensively, counted and plated at 2500 cells per well in 96 well plates before addition of the T cells. The plates are incubated for 4 hours at 37°C in 5% CO₂ before harvesting. Controls include T cell clone cultured alone or with target cells in the absence of peptides. Assays were set up in triplicate in 96 well plates with an effector to target ratio of 20 to 1.

The sensitivity of a T cell clone to a particular peptide identified above may also be determined using a dose-response experiment. Peptide sensitised fibroblasts can be used as target cells. The target cells are pulsed with the particular peptide as described above for fine specificity determination, with the exception that the peptides are added at different concentrations before the addition of T cells. Controls include target cells alone and target cells pulsed with the irrelevant melanoma associated peptide Melan-A/Mart-1.

Biological experiments/ Description of the figures:

Figure 1

Figure 1 (Fig. 1) describes the induction of telomerase (hTERT) reactive cytotoxic T lymphocytes (CTL's) in HLA-A2 (A2/K^b) transgenic mice immunized with telomerase peptides with sequence identity 9 and 10. A standard HLA-A2 restricted influenza (58-66) peptide was used as control. Three groups of five mice each were given two weekly subcutaneous injections of 10⁷ irradiated, peptide pulsed (100 µg/ml) syngeneic spleen cells. One week after the second injection, the mice were sacrificed and their spleens harvested. Spleen cells were prepared by standard techniques, and cells from primed animals were restimulated in vitro for 5 days by coculture with peptide pulsed (10 µg/ml) irradiated autologous spleen cells as antigen presenting cells before testing of cytotoxicity against hTERT expressing target cells (Jurkat) transfected with HLA-A2 (A2/K^b) in a ⁵¹Cr release assay.

Columns to the left of Fig. 1 show killing of HLA-A2 transfected Jurkat cells pulsed with the control peptide (influenza 58-66) by T cells obtained after priming of mice

with the peptide with sequence identity 9, at different effector to target ratios. Specific cytotoxicity above background was observed at all effector to target ratios. Columns in the middle show similar data with T cells obtained from mice primed with the peptide with sequence identity 10. Significant killing of Jurkat cells was only observed when spleen cells from telomerase peptide pulsed mice were used as effector cells, thus when spleen cells from influenza peptide primed mice were used as effectors, only background level of killing of Jurkat cells was seen when the target cells were pulsed with an irrelevant peptide (melanocortin receptor 1 peptide, MC1R244) as evident from columns in the right part of Fig. 1. These results demonstrate that the peptides with sequence identity 9 and 10 are immunogenic in vivo and upon immunization may elicit an immune response in a warm blooded animal carrying the common human MHC molecule HLA-A2. This finding indicates that the peptides with seq. id. no. 9 and 10 may also be used as a cancer vaccine in humans carrying HLA-A2 and other HLA class I molecules capable of binding these peptides. Furthermore, these results demonstrate that hTERT expressed by the T cell leukemia line Jurkat can be processed by the proteolytic machinery of the cell line to yield peptide fragments identical with or similar to the peptides with sequence identity 9 and 10. Together these observations indicate that an immune response obtained after vaccination of cancer patients or patients at risk of developing cancer with these peptides may result in efficient killing of tumor cells expressing the hTERT subunit of telomerase.

Fig. 1 depicts cytotoxicity of HLA-A2 transfected Jurkat cells with effector cells obtained from mice immunized as indicated in the figure. Target cells were labeled with ⁵¹Cr (0,1 µCi/100 µl cell suspension) for 1 hr. at 37 °C, washed twice and pulsed with peptide (1 µg/ml) for 1 hr at 37 °C before washing. Two thousand labeled, peptide pulsed target

Figure 2 (Fig. 2) shows the results of in vitro stimulation of peripheral blood T cells from a patient (TT) with colon cancer with telomerase (hTERT) derived peptides with sequence identity number 2, 3, 4 and 7. In vitro culture was performed as follows: Triplicates of 10^5 mononuclear cells were incubated for 6 days in X-VIVO 10 medium supplemented with 15% pooled heat inactivated human serum in a humidified incubator in 5% CO₂. Peptides were present throughout culture at a final concentration of 30 µg/ml in the medium. Cultures without peptide served as control. A proliferative response above background values was seen when the T cells were stimulated with the peptide with sequence identity 4. These results demonstrate that blood from a cancer patient contains circulating T cells specific for a peptide derived from telomerase (hTERT). These results demonstrate that the enzymatic subunit of telomerase (hTERT) is immunogenic in man, and may spontaneously give rise to telomerase specific T cell responses when overexpressed by a tumor growing in the patient. Furthermore, one component of the telomerase specific response in this patient is directed against the peptide with seq. id. no. 4 described here. This finding indicates that the peptide with seq. id. no. 4 may also be used as a cancer vaccine in humans. The figure depicts the

results of conventional T cell proliferative assays, where peripheral blood mononuclear cells (10^5) were cultured with peptides as indicated for 7 days in triplicates before harvesting. To measure the proliferative capacity of the cultures, ^3H -thymidine (3.7×10^4 Bq/ well) was added to the culture overnight before harvesting. Values are given as mean counts per minute (cpm) of the triplicates.

Figures 3 and 4

Figures 3 and 4 (Fig. 3 and Fig. 4) show the reactivity of tumor infiltrating lymphocytes (TILs) obtained from a patient with advanced pancreatic cancer. The T cells were obtained from a tumor biopsy and was successfully propagated *in vitro* to establish a T cell line. The T cell line was CD3+, CD4+ and CD8-, and proliferated specifically in response to the telomerase peptides. The results in Fig. 3 show T cells that recognise the peptides with seq. id. no. 2 and 3 when compared to controls with medium alone. The results in Fig. 4 show T cells that recognise the peptide with seq. id. no. 2. The TILs were expanded by co-cultureing with recombinant human interleukin 2 (rIL-2) and tested after 14 days in standard proliferation assay using peptides with sequence id. nos. 2, 3, 4 and 7.

Table 1

LMSVYVVEL	FLHWLMSVYVVELLRSFFYVTE
ELLRSFFYV	EARPALLTSRLRFIPK
YVVELLRSF	DGLRPIVNMDYVVGAR
VVELLRSFF	GVPEYGCVVNLRKVVNF
SVYVVELLR	
VELLRSFFY	
YVTETTFQK	
RLFFYRKSV	
SIGIRQHLK	
RPALLTSRL	
ALLTSRLRF	
LLTSRLRFI	
RPIVNMDYV	
LRPIVNMDY	
YVVGARTFR	
VVGARTFRR	
GARTFRREK	
ARTFRREKP	
PELYFVKV	
ELYFVKVDV	
FVKVDVTGA	
IPQDRLTEV	
DRLTEVIAS	
RLTEVIASI	
IPQGSILSTL	
ILSTLLCSL	
LLRLVDDFL	
RLVDDFLLV	
VPEYGCVVN	
VPEYGCVVNL	
TLVRGVPEY	
FLRTLVRGV	
GVPEYGCVV	
VVNLRKTVV	
GLFPWCGLL	

Table 2

YAETKHFLY
ISDTASLCY
DTDPRRLVQ
AQDPPPELY
LTDLQPYMR
QSDYSSYAR

ILAKFLHWL
ELLRSFFYV
LLARCALFV
WLCHQAFL
RLVDDFLLV
RLFFYRKSV
LQLPFHQV
RLGPQGWRL
SLQELTWKM
NVLAFGFAL
VLLKTHCPL
FLLVTPHLT
TLTDLQPYM
RLTEVIASI
FLDLQVNSL
SLNEASSGL
ILSTLLCSL
LLGASVLGL
VLAFGFALL
LQPYMRQFV
LMSVYVVEL
RLPQRYWQM
RQHSSPWQV
YLPNTVTDA
NMRRKLFGV
RLTSRVKAL
LLQAYRFHA
LLDTRTLEV
YMRQFVAHL
LLTSRLRFI
CLVCVPWDA
LLSSLRPSL

Table 2 (Continued)

FMCHHAVRI
LQVNSLQTV
LVAQCLVCV
CLKELVARV
FLRNTKKFI
ALPSDFKTI
VLVHLLARC
VQSDYSSYA
SVWSKLQSI
KLPGTTLTA
QLSRKLPGT
ELYFVKVDV
GLLLDTRTL
WMPGTPRRL
SLTGARRLV
VVIEQSSSL
LPSEAVQWL
QAYRFHACV

GLFDVFLRF
KLFGVLRK
RLREEILAK
TLVRGVPEY
GLPAPGARR
GLFPWCGLL
KLTRHRVTY
VLPLATFVR
ELVARVLQR

DPRRLVQLL
FVRACLRRRL
SVREAGVPL
AGRNMRRL
LARCALFVL
RPAEEATSL
LPSDFKTI
LPSEAVQWL
LPGTTLTAL
RPSFLLSSL
LPNTVTDAL
RPALLTSRL

Table 2 (Continued)

RCRAVRSLL

MPRAPRCRA

GIRRDGLLL

VLRKCHSL

YMRQFVAHL

SLRTAQTQL

QMRPLFLEL

LLRLVDDFL

FVQMPAHGL

HASGPRRRL

VVIEQSSSL

RVISDTASL

CVPAAEHRL

RVKALFSVL

NVLAFGFAL

LVARVLQRL

FAGIRRDGL

HAQCPYGVL

RAQDPPPEL

AYRFHACVL

HAKLSLQEL

GAKGAAGPL

TASLCYSIL

APRCRAVRS

GARRLVETI

AQCPYGVLL

HAKTFLRTL

EATSLEGAL

KAKNAGMSL

AQTQLSRKL

AGIRRDGLL

VLRKCHSL

ILKAKNAGM

DPRRLVQLL

GAKGAAGPL

FAGIRRDGL

GARRRGGSA

HAKTFLRTL

HAKLSLQEL

Table 2 (Continued)

LARCALFVL

EHRLREEIL

NMRRKLFGV

CAREKPQGS

LTRHRVTYV

RRFLRNTHK

RRDGLLLRL

RREKRAERL

RRLVETIFL

LRFMCHHAV

RRYAVVQKA

KRAERLTSR

RRKLFGVLR

RRRGGSASR

RRLPRLPQR

RRLGPQGWR

LRGSGAWGL

HREARPLL

VRRYAVVQK

ARTSIRASL

HRVTYVPLL

LRSHYREVL

MRPLFLELL

HRAWRTFVL

MRRKLFGVL

LRLVDDFLL

LRRVGDDVL

YRKSVWSKL

QRLCERGAK

FRALVAQCL

SRKLPGTTL

LRRLVPPGL

RRSPGVGCV

RRVGDDVLV

VRGCAWLRR

VRSLLRSHY

ARTFRREKR

SRSLPLPKR

IRASLTFNR

AEVRQHREA
REAGVPLGL
EEATSLEGA
LEAAANPAL
QETSPLRDA
REVLPLATF

Table 2 (Continued)

KEQLRPSFL
REKPQGSVA
LEVQSDYSS
REARPALLT
EEDTDPRRL
REEILAKFL
CERGAKNVL
DDVLVHLLA
GDMENKLFA
YERARRPGL

Att 34

CLAIMS

1. A telomerase peptide for use in a method of treatment or prophylaxis of cancer, characterised in that the telomerase peptide is capable of generating a T cell response directed against telomerase, and comprises a sequence EARPALLTSRLRFIPK (SEQ ID NO: 2), DGLRPIVNMDYVVGAR (SEQ ID NO: 3), GVPEYGCVVNLRKTVVNF (SEQ ID NO: 4), ILAKFLHWL (SEQ ID NO: 9) or ELLRSFFYV (SEQ ID NO: 10).
2. A nucleic acid for use in a method of treatment or prophylaxis of cancer, the nucleic acid being capable of encoding a telomerase peptide capable of generating a T cell response directed against telomerase, the peptide having a sequence EARPALLTSRLRFIPK (SEQ ID NO: 2), DGLRPIVNMDYVVGAR (SEQ ID NO: 3), GVPEYGCVVNLRKTVVNF (SEQ ID NO: 4), ILAKFLHWL (SEQ ID NO: 9) or ELLRSFFYV (SEQ ID NO: 10).
3. A telomerase peptide according to Claim 1 or a nucleic acid according to Claim 2 for a use as specified therein, in which the treatment or prophylaxis comprises administering to a mammal suffering or likely to suffer from cancer a therapeutically or prophylactically effective amount of the telomerase peptide so that a T cell response directed against the telomerase is induced in the mammal.
4. A telomerase peptide as claimed in Claims 1 or 3 or a nucleic acid as claimed in Claims 2 or 3 for a use as specified therein, in which the T cell response induced is a cytotoxic T cell response.
5. A pharmaceutical composition comprising at least one telomerase peptide as claimed in any of Claims 1, 3 or 4, or at least one nucleic acid as claimed in Claim 2, together with a pharmaceutically acceptable carrier or diluent.

6. A method for the preparation of a pharmaceutical composition as claimed in Claim 5, in which the method comprises mixing at least one telomerase peptide as claimed in any of Claims 1, 3 and 4, or at least one nucleic acid as claimed in Claim 2, with a pharmaceutically acceptable carrier or diluent.

7. A pharmaceutical composition comprising a combination of at least one telomerase peptide as claimed in any of Claims 1, 3 or 4 and at least one peptide capable of inducing a T cell response directed against an oncogene or mutant tumour suppressor protein or peptide, together with a pharmaceutically acceptable carrier or diluent.

8. A method for the preparation of a pharmaceutical composition as claimed in Claim 7, in which the method comprises mixing at least one telomerase peptide as claimed in any of Claims 1, 3 and 4, with at least one peptide capable of inducing a T cell response directed against an oncogene or mutant tumour suppressor protein or peptide, and a pharmaceutically acceptable carrier or diluent.

9. A pharmaceutical composition as claimed in Claim 7 or a method of making a pharmaceutical composition as claimed in Claim 8, in which the oncogene protein or peptide is a mutant p21-ras protein or peptide, or in which the tumour suppressor protein or peptide is a retinoblastoma or p53 protein or peptide.

10. A telomerase peptide as claimed in any of Claims 1, 3 and 4, a nucleic acid as claimed in Claim 2, or a pharmaceutical composition as claimed in Claims 5, 7 or 9, in which the cancer is selected from breast cancer, prostate cancer, pancreatic cancer, colorectal cancer, lung cancer, malignant melanoma, leukaemias, lymphomas, ovarian cancer, cervical cancer and biliary tract carcinomas.

11. A method of generating T lymphocytes capable of recognising and destroying tumour cells in a mammal, in which the method comprises taking a sample of T lymphocytes from a mammal and culturing the T lymphocyte sample in the presence of a telomerase peptide in an amount sufficient to generate telomerase specific T lymphocytes, in which the telomerase peptide comprises a sequence EARPALLTSRLRFIPK (SEQ ID NO: 2), DGLRPDIVNMDYVVGAR (SEQ ID NO: 3), GVPEYGCVVNLRKTVVNF (SEQ ID NO: 4), ILAKFLHWL (SEQ ID NO: 9) or ELLRSFFYV (SEQ ID NO: 10).

12. A telomerase specific T lymphocyte generated by a method according to Claim 11.

13. A pharmaceutical composition comprising a telomerase specific T lymphocyte according to Claim 12, together with a pharmaceutically acceptable carrier.

14. The use of a telomerase peptide for the manufacture of a medicament for the treatment or prophylaxis of cancer, in which the telomerase peptide is capable of generating a T cell response directed against telomerase, the peptide comprising a sequence EARPALLTSRLRFIPK (SEQ ID NO: 2), DGLRFIVNMDYVVGAR (SEQ ID NO: 3), GVPEYGCVVNLRKTVVNF (SEQ ID NO: 4), ILAKFLHWL (SEQ ID NO: 9) or ELLRSFFYV (SEQ ID NO: 10).

15. A telomerase peptide for use in a method of treatment or prophylaxis of cancer substantially as hereinbefore described with reference to and as shown in the drawings.

16. The use of a telomerase peptide, or a nucleic acid capable of encoding a telomerase peptide, for the preparation of a medicament for the treatment or prophylaxis of cancer, substantially as hereinbefore described with reference to and as shown in the drawings.

17. A nucleic acid capable of encoding a telomerase peptide for use in a method of treatment or prophylaxis of cancer substantially as hereinbefore described with reference to and as shown in the drawings.

18. A pharmaceutical composition or a method of preparation of such a pharmaceutical composition comprising at least one telomerase peptide substantially as hereinbefore described with reference to and as shown in the drawings.

19. A method of generating telomerase T lymphocytes substantially as hereinbefore described.

20. A method of treatment or prophylaxis of cancer, the method comprising administering a therapeutically or prophylactically effective amount of telomerase peptide to a mammal suffering or likely to suffer from cancer, in which the telomerase peptide is capable of generating a T cell response directed against telomerase, and comprises a sequence EARPALLTSRLRFIPK (SEQ ID NO: 2), DGLRPIVNMDYVVGAR (SEQ ID NO: 3), GVPEYGCVVNLRKTVVNF (SEQ ID NO: 4), ILAKFLHWL (SEQ ID NO: 9) or ELLRSFFYV (SEQ ID NO: 10).

21. A method of treatment or prophylaxis of cancer, the method comprising administering a therapeutically or prophylactically effective amount of a nucleic acid to a mammal suffering or likely to suffer from cancer, in which the nucleic acid is capable of encoding a telomerase peptide capable of generating a T cell response directed against telomerase, the peptide having a sequence EARPALLTSRLRFIPK (SEQ ID NO: 2), DGLRPIVNMDYVVGAR (SEQ ID NO: 3), GVPEYGCVVNLRKTVVNF (SEQ ID NO: 4), ILAKFLHWL (SEQ ID NO: 9) or ELLRSFFYV (SEQ ID NO: 10).

22. A method of treatment or prophylaxis of cancer, the method comprising administering a therapeutically or prophylactically effective amount of a telomerase peptide and a peptide capable of inducing a T cell response against an oncogene or mutant tumour suppressor protein or peptide to a mammal suffering or likely to suffer from cancer, in which the telomerase peptide is capable of generating a T cell response directed against telomerase, and comprises a sequence EARPALLTSRLRFIPK (SEQ ID NO: 2), DGLRPIVNMDYVVGAR (SEQ ID NO: 3), GVPEYGCVVNLRKTVVNF (SEQ ID NO: 4), ILAKFLHWL (SEQ ID NO: 9) or ELLRSFFYV (SEQ ID NO: 10).

23. A method of treatment or prophylaxis of cancer, the method comprising:

(a) taking a sample of T lymphocytes from a mammal;

(b) culturing the T lymphocyte sample in the presence of a telomerase peptide in an amount sufficient to generate telomerase specific T lymphocytes capable of recognising and destroying cancer cells in a mammal, the telomerase peptide comprising a sequence EARPALLTSRLRFIPK (SEQ ID NO: 2), DGLRPIVNMDYVVGAR (SEQ ID NO: 3), GVPEYGCVVNLRKTVVNF (SEQ ID NO: 4), ILAKFLHWL (SEQ ID NO: 9) or ELLRSFFYV (SEQ ID NO: 10); and

(c) administering a therapeutically or prophylactically effective amount of the cultured T lymphocytes to a mammal suffering or likely to suffer from cancer.

1 5

1 5

1/4




Fig. 1

2/4




Fig. 2

3/4




Fig. 3

4/4




Fig. 4

**COMBINED DECLARATION AND POWER OF ATTORNEY
FOR PATENT APPLICATION**

(Page 1)

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled ANTIGENIC PEPTIDES DERIVED FROM TELOMERASE

the specification of which ☐ is attached hereto ☒ was filed on 30 June 1999 PCT International Application No. PCT/NO99/00220 and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR §1.56

I hereby claim foreign priority benefits under 35 U.S.C. §119(a)-(d) or §365(b), of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT international application which designates at least one country other than the United States, listed below and have also identified below any foreign application for patent or inventor's certificate, or PCT international application having a filing date before that of the application on which priority is claimed:

Country	Application No.	Filed (Day/Mo./Yr.)	(Yes/No) Priority Claimed
NORWAY	19983141	8 July 1998	Yes

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT international application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 C.F.R. § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

Application No.	Filed (Day/Mo./Yr.)	Status (Patented, Pending, Abandoned)
-----------------	---------------------	--

I hereby appoint the practitioners associated with the firm and Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to the address associated with that Customer Number

FITZPATRICK, CELLA, HARPER & SCINTO
Customer Number: 05514

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Sole or First Inventor FAD Gustav GAUDERNACK
First Inventor's signature Gustav Gaudernack
Date January 19, 2001 Citizen/Subject of Norway
Residence Det Norske Radiumhospital, Ullernch. 70, N-0310 Oslo,
Norway
Post Office Address N-0240 Oslo, Norway

002432931.070501
COMBINED DECLARATION AND POWER OF ATTORNEY
FOR PATENT APPLICATION

(Page 2)

20
Full Name of Second Joint Inventor, if any Jon Amund ERIKSEN
Second Inventor's signature Jon A. Eriksen
Date 18th January 2001 Citizen/Subject of Norway
Residence Bjørntvedt gt. 37, N-3916 Porsgrunn, Norway NOX
Post Office Address N-0240 Oslo, Norway

30
Full Name of Third Joint Inventor, if any Mona MØLLER
Third Inventor's signature Mona Møller
Date 18/01/2001 Citizen/Subject of Norway
Residence Skrukerødtoppen 8, N-3925 Porsgrunn, Norway NOX
Post Office Address N-0240 Oslo, Norway

40
Full Name of Fourth Joint Inventor, if any Marianne Klemp GJERTSEN
Fourth Inventor's signature M.K. Gertsen
Date 26 January 2001 Citizen/Subject of Norway
Residence Det Norske Radiumhospital, Ullernch. 70, N-0310 Oslo,
Norway NOX
Post Office Address N-0240 Oslo, Norway

50
Full Name of Fifth Joint Inventor, if any Ingvil SÆTERDAL
Fifth Inventor's signature Ingvil Sæterdal
Date 22/01/2001 Citizen/Subject of Norway
Residence Det Norske Radiumhospital, Ullernch. 70, N-0310 Oslo,
Norway NOX
Post Office Address N-0240 Oslo, Norway

60
Full Name of Sixth Joint Inventor, if any Stein SÆBØE-LARSEN
Sixth Inventor's signature Stein Sæbøe-Larsen
Date 26/01/2001 Citizen/Subject of Norway
Residence Det Norske Radiumhospital, Ullernch. 70, N-0310 Oslo,
Norway NOX
Post Office Address N-0240 Oslo, Norway